Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Elicio Therapeutics is a clinical-stage immuno-oncology company developing lymph node-targeted cancer vaccines using its proprietary Amphiphile (AMP) platform technology. The company's lead candidate, ELI-002, targets KRAS-mutated cancers (pancreatic and colorectal), with Phase 2 trials ongoing as of February 2026. With zero revenue, $100M market cap, and negative operating cash flow, ELTX is a binary-outcome biotech dependent on clinical trial readouts and capital raises.
Elicio operates a typical clinical-stage biotech model: burn cash on R&D to advance drug candidates through FDA trials (Phase 1/2/3), then monetize via product commercialization or acquisition. The AMP platform targets lymph nodes to amplify immune response, theoretically improving vaccine efficacy versus systemic delivery. Pricing power depends entirely on clinical differentiation - if ELI-002 demonstrates superior progression-free survival in KRAS+ pancreatic cancer versus standard-of-care, it could command premium pricing in a $2B+ addressable market. Current business model is capital-intensive with no near-term revenue, relying on equity/debt financing to fund $30-40M annual burn rate.
Phase 2 clinical trial data readouts for ELI-002 in KRAS-mutated pancreatic and colorectal cancer - interim analysis results on progression-free survival and overall response rates
FDA regulatory milestones - IND approvals for new indications, Fast Track or Breakthrough Therapy designations that accelerate development timelines
Capital raises and cash runway updates - equity offerings, debt financing, or strategic partnerships that extend operational runway beyond current 2-3 year estimate
Competitive landscape shifts - rival KRAS-targeted therapies (Amgen's Lumakras, Mirati's Krazati) showing efficacy/safety issues or new entrants validating the target
Partnership announcements with Big Pharma for co-development, commercialization rights, or platform technology licensing deals
Binary clinical trial risk - Phase 2 failure for ELI-002 would likely result in 60-80% stock decline given single-asset concentration. KRAS has historically been 'undruggable' with high failure rates.
FDA regulatory pathway uncertainty - immuno-oncology endpoints (PFS, OS) require large trials and long follow-up. Accelerated approval pathways depend on demonstrating substantial improvement over existing therapies in difficult-to-treat populations.
Competitive obsolescence - rapid innovation in cancer immunotherapy (CAR-T, bispecifics, ADCs) could render vaccine approaches less attractive. Merck, BMS, and Roche dominate checkpoint inhibitor market with established infrastructure.
Direct KRAS competitors with superior data - Amgen's Lumakras and Mirati's Krazati already approved for KRAS G12C mutations. If ELI-002 targets same mutations, it faces high bar for differentiation.
Big Pharma in-house programs - companies like Moderna, BioNTech developing mRNA cancer vaccines with deeper pockets and faster enrollment capabilities. Platform risk if AMP technology doesn't demonstrate clear superiority.
Cash runway risk - with $30-40M annual burn and ~$100M market cap, likely needs financing within 12-18 months. At 37.6x price/book, equity raises would be highly dilutive to existing shareholders.
Debt covenant risk - 1.40x debt/equity suggests term loans or convertible notes outstanding. If trials miss milestones, could trigger covenant violations or forced conversion at unfavorable terms.
Going concern risk - negative $162% ROA indicates asset base cannot support operations. Auditors may flag going concern if cash drops below 12-month runway without committed financing.
low - Clinical-stage biotech revenue is non-existent, insulating from GDP fluctuations. However, financing environment is cyclical: risk appetite for speculative biotech correlates with economic expansion. In recessions, Series B/C rounds become scarce and valuations compress, forcing dilutive raises or asset sales.
High sensitivity through multiple channels: (1) Valuation - biotech DCF models discount future cash flows 8-15 years out, so rising rates (GS10) compress NPV significantly. A 100bp rate increase can reduce pre-revenue biotech valuations 20-30%. (2) Financing costs - if ELTX taps debt markets, higher FEDFUNDS increases interest expense on any term loans or convertible notes. (3) Opportunity cost - rising 10Y yields make risk-free Treasuries more attractive versus speculative biotech, reducing investor appetite. Current 1.40x debt/equity suggests some leverage, making rate sensitivity material.
Moderate - While ELTX doesn't rely on consumer/corporate credit for revenue, access to capital markets (equity and convertible debt) depends on credit conditions. Widening high-yield spreads (BAMLH0A0HYM2) signal risk-off sentiment, making it harder to raise capital on favorable terms. Clinical-stage biotechs often use convertible notes; tightening credit increases conversion premiums and dilution risk.
growth/speculative - Attracts biotech-focused hedge funds, venture capital crossover funds, and retail investors seeking asymmetric upside from clinical catalysts. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend. Typical holder has 2-5 year horizon aligned with Phase 2/3 trial timelines and expects 3-5x return on success or near-total loss on failure. High concentration risk given single lead asset.
high - Clinical-stage biotechs exhibit 80-120% annualized volatility driven by binary trial readouts. ELTX's -12.7% six-month return and 6.7% one-year return mask intra-period swings likely exceeding 30-40% on data releases. Low float ($100M market cap) amplifies volatility on news. Beta to broader market likely <0.5 as stock-specific catalysts dominate over macro factors, but correlation spikes during risk-off periods when speculative assets sell indiscriminately.